BUTYRIC ACID AND INULIN IN THE COMBINATION TREATMENT OF ABDOMINAL PAIN IN IRRITABLE BOWEL SYNDROME


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The combination of trimebutine and Zacofalc has been shown to surpass that of trimebutine and lactobacteria in efficacy when comparing the magnitude of pain syndrome (p=0.04) and the intensity of painful sensations (p=0.042). The former combination is an effective agent for the therapeutic correction of abdominal pain in patients with irritable bowel syndrome.

Full Text

Restricted Access

About the authors

A. Nizhevich

Bashkir State Medical University

Email: aanj@yandex.ru

E. Koroleva

OOO «Endomed», Gastrocenter Clinic

E. Astrelina

OOO «Endomed», Gastrocenter Clinic

V. Alyangin

Bashkir State Medical University; OOO «Endomed», Gastrocenter Clinic

References

  1. Пиманов С.И., Силивончик Н.Н. Римский III консенсус: Избранные разделы и комментарии / Витебск: Издательство ВГМУ, 2006; 160 с.
  2. Шептулин А.А. Римские критерии III синдрома раздраженного кишечника: что мы ожидали и что мы увидели? // РЖГГК. - 2007; 2: 63-8.
  3. Rey E., Talley N. Irritable bowel syndrome: Novelviews on the epidemiology and potential risk factors // Dig. Liver Dis. - 2009; 41: 772-80.
  4. Gweek A., Wee S., Wong M. et al. The prevalence, symptom chаrаcteristics and impact of irritable bowel syndrome in an Asian urban community // Am. J. Gastroenterol. - 2004; 99: 924-31.
  5. Mangel A., Northcutt A. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients // Aliment. Pharmacol. Ther. - 1999; 13 (Suppl. 2): 77-82.
  6. Ghoshal U., Abraham P., Bhatt C. et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology task force // Indian J. Gastroenterol. - 2008; 27 (1): 22-8.
  7. Whitehead W., Crowell M., Davidoff A. et al. Pain from rectal distension in women with irritable bowel syndrome // Dig. Dis. Sci. - 1997; 42: 796-804.
  8. Whitehead W., Holtkotter B., Enck P. et al. Tolerance for rectosigmoid distension in irritable bowel syndrome // Gastroenterology. - 1990; 98: 1187-92.
  9. Ардатская М.Д. Масляная кислота и инулин в клинической практике: теоретические аспекты и возможности клинического применения / М.: Фортепринт, 2014; 64 c.
  10. Banasiewicz T., Kaczmarek E., Maik J. et al. Quality of life andthe clinical symptoms at the patients with irritable bowel syndrometreated complementary with protected sodium butyrate // Gastroenterol. Prakt. - 2011; 5: 45-53.
  11. Banasiewicz T., Kaczmarek E., Maik J. et al. The influence of protected sodium butyrate on frequency and severity some clinicalsymptoms at the patients with irritable bowel syndrome // Gastroenterol. Prakt. - 2012; 1: 16-23.
  12. Tarnowski W., Borycka-Kiciak K., Kiciak A. et al. Outcome oftreatment with butyric acid in irritable bowel syndrome - preliminaryreport // Gastroenterol. Prakt. - 2011; 1: 43-8.
  13. Vanhoutvin S., Troost F., Kilkens T. et al. The effects of butyrate enemas on visceral perception in healthy volunteers // Neurogastroenterol. Motil. - 2009; 21 (9): 952-76.
  14. Маев И.В., Кучерявый Ю.А., Черемушкин С.В. Эволюция представлений о синдроме разраженного кишечника. Методические рекомендации для врачей / М., 2013; 80 с.
  15. Васильев Ю.В. Синдром раздраженного кишечника: современные аспекты диагностики и терапии // Мед. Совет. - 2014; 4: 72-7.
  16. Nijevitch A., Akhmadeeva E., Sataev V. et al. Efficacy of Trimebutine Maleate in the Treatment of Functional Dyspepsia in Childhood // J. Nepal. Paediatr. Soc. - 2013; 33 (2): 158-62.
  17. Delvaux M., Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results // J. Int. Med. Res. - 1997; 25 (5): 225-46.
  18. Lee H., Kim B. Trimebutine as a modulator of gastrointestinal motility // Arch. Pharm. Res. - 2011; 34 (6): 861-4.
  19. Fioramonti J., Bueno L. Centrally acting agents and visceral sensitivity // Gut. - 2002; 51 (Suppl. 1): 91-5.
  20. Sarnelli G. Gut microbiota and irritable bowel syndrome: a further link between the big brain - little brain axis // J. Prob. Health. - 2014; 2 (2): 107.
  21. Lee K., Tack J. Altered intestinal microbiota in irritable bowel syndrome // Neurogastroenterol. Motil. - 2010; 22 (5): 493-8.
  22. Collins S., Denou E., Verdu E. et al. The putativerole of the intestinal microbiota in the irritable bowel syndrome // Dig. Liver Dis. - 2009; 41 (12): 850-3.
  23. Sudo N., Chida Y., Aiba Y. et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice // J. Physiol. - 2004; 558 (Pt. 1): 263-75.
  24. Kunze W., Mao Y., Wang B. et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening // J. Cell. Mol. Med. - 2009; 13 (8B): 2261-70.
  25. Salonen A., de Vos W., Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives // Microbiology. - 2010; 156 (Pt. 11): 3205-15.
  26. Topping D., Clifton P. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides // Physiol. Rev. - 2001; 81 (3): 1031-64.
  27. Załęski A., Banaszkiewicz A., Walkowiak J. Butyric acid in irritable bowel syndrome // Prz. Gastroenterol. - 2013; 8 (6): 350-3.
  28. Guilloteau P., Martin L., Eeckhaut V. et al. From the gut to the peripheral tissues: the multiple effects of butyrate // Nutr. Res. Rev. - 2010; 23 (2): 366-84.
  29. Ерофеев Н.П., Радченко В.Г., Селиверстов П.В. Клиническая физиология толстой кишки. Механизмы действия короткоцепочечных жирных кислот в норме и при патологии: монография / СПб: Форте Принт, 2012; 56 с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies